Sangamo Therapeutics IncAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Tag Archive for: Licence
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform.
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.